<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225822</url>
  </required_header>
  <id_info>
    <org_study_id>1160.19</org_study_id>
    <nct_id>NCT01225822</nct_id>
  </id_info>
  <brief_title>BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery</brief_title>
  <official_title>BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to establish the dose-response relationship with
      regard to efficacy and safety of BIBR 1048 (50 mg bis in die(b.i.d), 150 mg b.i.d, 225 mg
      b.i.d. and 300 mg quaque die(q.d) ) in preventing venous thromboembolism(VTE) in patients
      undergoing primary elective total hip and knee replacement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Venous Thromboembolic (VTE) Events</measure>
    <time_frame>Treatment period (up to day 8+/-2 days visit)</time_frame>
    <description>Deep vein thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or PE confirmed by objective testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Major Bleeding Events (MBE)</measure>
    <time_frame>From approximately 14 days prior to surgery to 4-6 weeks post surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With VTE Events and All Cause Mortality</measure>
    <time_frame>Treatment period (up to day 8+/-2 days visit)</time_frame>
    <description>Deep venous thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or Pulmonary Embolism (PE) confirmed by objective testing and all deaths.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Proximal DVT, PE (Pulmonary Embolism) and VTE Related Mortality</measure>
    <time_frame>Treatment period (up to day 10)</time_frame>
    <description>Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period or PE confirmed by objective testing plus VTE related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Proximal DVT</measure>
    <time_frame>Treatment period (up to day 8+/-2 days visit)</time_frame>
    <description>Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Blood Loss</measure>
    <time_frame>Day 1 (Day of surgery)</time_frame>
    <description>Volume of blood loss was to be analysed using an analysis of variance (ANOVA), which included treatment and centre.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Transfusions Due to Bleedings</measure>
    <time_frame>Day 1 (Day of surgery)</time_frame>
    <description>Percentage of patients requiring transfusions due to bleeding .Rate of need of transfusion were to be analysed using a logistic regression with treatment and centre.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant, Minor or Any Bleeding Events</measure>
    <time_frame>Treatment period (up to day 8+/-2 days visit)</time_frame>
    <description>Number of participants with Clinically Significant, minor or any bleeding events. Clinically significant bleeding events are defined as
Spontaneous skin haematoma larger than &gt;25 cm²
Wound haematoma &gt;100 cm²
Spontaneous nose bleed &gt;5 minutes
Macroscopic haematurea, either spontaneous or lasting more than 24 hours if associated with an intervention
Spontaneous rectal bleeding (more than spot on toilet paper)
Gingival bleeding &gt;5 minutes
Any other bleeding event considered as clinically significant by the investigator All other bleeding events that did not fulfil the criteria of MBE or clinically significant bleeding event were classified as minor bleeding events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Analyses</measure>
    <time_frame>Screening to end of treatment</time_frame>
    <description>Number of patients with possible clinically significant abnormalities, i.e. with values out of normal range.
Normal ranges are defined as:
Haematocrit [%]: (0.35-0.45) for women and (0.39−0.51) for men Haemoglobin [g/dL]: (11.6−15.4) for women and (13.2−17.3) for men White Blood Cell count [10^9/L]: (4-10.3) for women and (3.9−10.3) for men Platelets [10^9/L]: (145-420) for women and men Sodium [mmol/L]: (135-146) for women and men Potassium [mmol/L]: (3.5-5) for women and men Aspartate aminotransferase (AST) [U/L]: (11-37) for women and (11-39) for men Alanine aminotransferase (ALT) [U/L]: (8-43) for women and (8-45) for men Alkaline Phosphatase [U/L]: (36-118) for women and (35-123) for men Creatinine [mg/dL]: (0.57-1.06)for women and (0.72−1.3) for men Bilirubin, total [mg/dL]: (0.22-1.28) for women and men Uric acid [mg/dL]: (2.4-6.47) for women and men</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration (Cmax) of Dabigatran</measure>
    <time_frame>Day 1 to end of treatment</time_frame>
    <description>Maximum plasma concentration of Dabigatran (at steady-state) and Pre-dose plasma concentrations at steady state.
Cmax represents the maximum concentration of Dabigatran in plasma. Cmax,ss represents the maximum concentration of Dabigatran in plasma at steady state.
Cpre,ss represents pre-dose concentration of Dabigatran in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve During a Dosing Interval</measure>
    <time_frame>up to day 8+/-2 days visit</time_frame>
    <description>Area under the plasma concentration-time curve during a dosing interval (at steady-state). The AUC0-12h (for b.i.d. treatment regimens) and AUC0-24h (300 mg q.d.) after the first dose on day of surgery calculated by extrapolation using the elimination rate constant, reported only if the extrapolated fraction of AUC was less than 30 % of the total AUC.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1973</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>BIBR 1048 50 mg bis in die(b.i.d)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIBR 1048 50 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus one placebo matching enoxaparin 0 mg once a day for the treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 150 mg b.i.d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIBR 1048 150 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 225 mg b.i.d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIBR 1048 225 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 300 mg quaque die(q.d)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIBR 1048 150 mg q.d once a day plus placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin 40 mg subcutaneous(s.c)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo matching BIBR 1048 0 mg twice a day plus enoxaparin 40 mg s.c once a day for the treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period</description>
    <arm_group_label>Enoxaparin 40 mg subcutaneous(s.c)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048</intervention_name>
    <description>50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period</description>
    <arm_group_label>BIBR 1048 50 mg bis in die(b.i.d)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048</intervention_name>
    <description>150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period</description>
    <arm_group_label>BIBR 1048 150 mg b.i.d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048</intervention_name>
    <description>225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period</description>
    <arm_group_label>BIBR 1048 225 mg b.i.d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048</intervention_name>
    <description>300 mg q.d BIBR 1048 capsule for 5-10 treatment period</description>
    <arm_group_label>BIBR 1048 300 mg quaque die(q.d)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Patients scheduled to undergo a primary elective total hip or knee replacement.

          2. Male of female being 18 years or older.

          3. Patients weighing at least 40 kg.

          4. Written informed consent for study participation.

        Exclusion criteria

          1. Bleeding diathesis, constitutional or acquired coagulation disorders.

          2. Major surgery or trauma(e.g., hip fracture) within the last 3 months.

          3. Cardiovascular disease

          4. Any history of haemorrhagic stroke, intracranial or intraocular bleeding or cerebral
             ischaemic attacks lasting more than 24 hours and / or with cardiovascular pathological
             findings.

          5. Deep vein thrombosis(DVT), gastrointestinal or pulmonary bleeding, gastric or duodenal
             ulcer within the last year.

          6. History of or acute intracranial disease

          7. Liver disease

          8. Renal disease

          9. Use of long-term anticoagulants or antiplatelet drugs within 7 days prior to hip/knee
             replacement operation.

         10. Pre-menopausal women who are not surgically steriles, are nursing and are of
             child-bearing potential and are not practising acceptable methods of birth control

         11. Known allergy to contrast media

         12. Thrombocytopenia

         13. Allergy against heparin.

         14. Active malignant disease or current cytostatic treatment.

         15. Treatment with an investigational drug in the past month.

         16. Leg amputee

         17. Known alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.19.43004 Krankenhaus der Barmherzigen Schwestern Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.43002 Orthopädisches Spital Speising</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.43001 A.ö. Krankenhaus d. Statutarstadt Wiener Neustadt</name>
      <address>
        <city>Wr. Neustadt</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.32002 V.U.B. Jette</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.32004 UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.32005 Virga Jesseziekenhuis</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.32006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huy</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.32007 C.H.U. de Tivoli</name>
      <address>
        <city>La Louvière</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.42004 University Hospital Brno</name>
      <address>
        <city>Brno-Bohunice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.42001 Hospital Kladno</name>
      <address>
        <city>Kladno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.42006 Hospital Mlada Boleslav</name>
      <address>
        <city>Mlada Boleslav</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.42003 University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.42005 University Hospital Plzen</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.42009 University Hospital Na Bulovce</name>
      <address>
        <city>Prague 8</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.45042 Orthopedic Surgical Clinic</name>
      <address>
        <city>Frederiksberg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.45045 Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.45043 Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.45041 Hørsholm Sygehus</name>
      <address>
        <city>Hørsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.45044 Orthopedic Surgical Dept.</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.35802 Keski-Suomen keskussairaala</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.35801 Oulun yliopistollinen sairaala, Leikkaus- ja tehohoidon yks.</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.33004 Div</name>
      <address>
        <city>Illkirch cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.33007 Clinique du Mail</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.33009 Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon cedex 03</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.33006 Clinique Mutualiste</name>
      <address>
        <city>Saint-Etienne cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.33008 Clinique de l'Atlantique</name>
      <address>
        <city>St Herblain cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.36003 Sándor Péterfy Hospital</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.36001 Kálmán Pándy County Hospital</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.36004 Bács-Kiskun County Hospital</name>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.36002 Albert Szent-Györgyi Medical and Pharmacological Center</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.36005 Szent György Hospital</name>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.39003 U. O. Ortopedia e Traumatologia</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.39005 Modulo Coordinazione Dipartimentale di Ricerca e Anestesia</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.39002 Fondazione Centro S. Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.39001 IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.39004 Ospedale di Circolo di Varese</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.31005 Hengstdal 3</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.47001 Nordlandssykehuset HF, Bodø</name>
      <address>
        <city>Bodø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.47004 Martina Hansens Hospital</name>
      <address>
        <city>Bærum Postterminal</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.47008 Martina Hansens Hospital</name>
      <address>
        <city>Bærum Postterminal</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.47007 Sykehuset Innlandet HF, Avd. Elverum</name>
      <address>
        <city>Elverum</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.47005 Haugesund sjukehus HF</name>
      <address>
        <city>Haugesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.47002 Sykehuset Telemark HF, Avd. Skien</name>
      <address>
        <city>Skien</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.47003 Helse Sunnmøre HF, Ålesund sykehus</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.27001 Dept. of Haematology</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.27002 Suite 203</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.46002 Kirurgavdelningen</name>
      <address>
        <city>Falköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.46001</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.46004 Ortopediska kliniken, Länssjukhuset, Halmstad</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.46003 Ortopediska kliniken, Länssjukhuset i Kalmar</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.46007 Kungälvs sjukhus</name>
      <address>
        <city>Kungälvs</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.46005 Kirurg Ortopediska kliniken, Sjukhuset i Lidköping</name>
      <address>
        <city>Lidköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.46008 Ortopediska Institutionen</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.46009 Sahlgrenska Universitetssjukhuset, Mölndal</name>
      <address>
        <city>Mölndal</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.19.46006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Varberg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>South Africa</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <results_first_submitted>November 18, 2010</results_first_submitted>
  <results_first_submitted_qc>November 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2010</results_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 1973 patients enrolled/randomised in this trial but only 1949 started treatment</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>BIBR 1048 50 mg Bid</title>
          <description>Dabigatran 50 mg bid(twice daily) oral</description>
        </group>
        <group group_id="P2">
          <title>BIBR 1048 150 mg Bid</title>
          <description>Dabigatran 150 mg bid(twice daily) oral</description>
        </group>
        <group group_id="P3">
          <title>BIBR 1048 225 mg Bid</title>
          <description>Dabigatran 225 mg bid(twice daily) oral</description>
        </group>
        <group group_id="P4">
          <title>BIBR 1048 300 mg qd</title>
          <description>Dabigatran 300 mg qd(once daily) oral</description>
        </group>
        <group group_id="P5">
          <title>Enoxaparin 40 mg qd</title>
          <description>Enoxaparin 40 qd (once daily) subcutaneous injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="389"/>
                <participants group_id="P2" count="390"/>
                <participants group_id="P3" count="393"/>
                <participants group_id="P4" count="385"/>
                <participants group_id="P5" count="392"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="351"/>
                <participants group_id="P2" count="334"/>
                <participants group_id="P3" count="355"/>
                <participants group_id="P4" count="333"/>
                <participants group_id="P5" count="361"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BIBR 1048 50 mg Bid</title>
          <description>Dabigatran 50 mg bid (twice daily) oral</description>
        </group>
        <group group_id="B2">
          <title>BIBR 1048 150 mg Bid</title>
          <description>Dabigatran 150 mg bid (twice daily) oral</description>
        </group>
        <group group_id="B3">
          <title>BIBR 1048 225 mg Bid</title>
          <description>Dabigatran 225 mg bid (twice daily) oral</description>
        </group>
        <group group_id="B4">
          <title>BIBR 1048 300 mg qd</title>
          <description>Dabigatran 300 mg qd (once daily) oral</description>
        </group>
        <group group_id="B5">
          <title>Enoxaparin 40 mg qd</title>
          <description>Enoxaparin 40 mg qd (once daily) subcutaneous injection</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="389"/>
            <count group_id="B2" value="390"/>
            <count group_id="B3" value="393"/>
            <count group_id="B4" value="385"/>
            <count group_id="B5" value="392"/>
            <count group_id="B6" value="1949"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Safety set population</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.07" spread="10.23"/>
                    <measurement group_id="B2" value="65.86" spread="10.77"/>
                    <measurement group_id="B3" value="65.87" spread="10.63"/>
                    <measurement group_id="B4" value="66.47" spread="10.37"/>
                    <measurement group_id="B5" value="65.03" spread="11.03"/>
                    <measurement group_id="B6" value="65.86" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Safety set population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="252"/>
                    <measurement group_id="B3" value="229"/>
                    <measurement group_id="B4" value="246"/>
                    <measurement group_id="B5" value="241"/>
                    <measurement group_id="B6" value="1191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="139"/>
                    <measurement group_id="B5" value="151"/>
                    <measurement group_id="B6" value="758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Venous Thromboembolic (VTE) Events</title>
        <description>Deep vein thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or PE confirmed by objective testing</description>
        <time_frame>Treatment period (up to day 8+/-2 days visit)</time_frame>
        <population>Full Analysis Set (FAS) population. This included all randomised patients who had at least one subcutaneous injection and one oral dose of study medication and with confirmed VTE data post surgery</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg Bid</title>
            <description>Dabigatran 50 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 150 mg Bid</title>
            <description>Dabigatran 150 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 225 mg Bid</title>
            <description>Dabigatran 225 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 300 mg qd</title>
            <description>Dabigatran 300 mg qd (once daily) oral</description>
          </group>
          <group group_id="O5">
            <title>Enoxaparin 40 mg qd</title>
            <description>Enoxaparin 40 mg qd (once daily) subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Venous Thromboembolic (VTE) Events</title>
          <description>Deep vein thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or PE confirmed by objective testing</description>
          <population>Full Analysis Set (FAS) population. This included all randomised patients who had at least one subcutaneous injection and one oral dose of study medication and with confirmed VTE data post surgery</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="375"/>
                <count group_id="O3" value="381"/>
                <count group_id="O4" value="371"/>
                <count group_id="O5" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 225 mg bid vs. BIBR 1048 50 mg bid comparison. The primary objective of the trial was to establish a dose relationship among BIBR 1048 doses studied in the prevention of VTE. The statistical model was a logistic regression which included treatment and centre..</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Dose relationship tested using a hierarchical testing procedure to preserve type I error rate at 5%. 225 mg bid was compared to 50 mg bid. If a difference significant at 5% level was found, then 150 mg bid was compared to 50 mg bid</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.375</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.244</ci_lower_limit>
            <ci_upper_limit>0.577</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 150 mg bid vs. BIBR 1048 50 mg bid comparison. The primary objective of the trial was to establish a dose relationship among BIBR 1048 doses studied in the prevention of VTE. The statistical model was a logistic regression which included treatment and centre..</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>Dose relationship tested using a hierarchical testing procedure to preserve type I error rate at 5%. 225 mg bid was compared to 50 mg bid. If a difference significant at 5% level was found, then 150 mg bid was compared to 50 mg bid</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.518</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.344</ci_lower_limit>
            <ci_upper_limit>0.778</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 300 mg qd vs. BIBR 1048 150 mg bid comparison. Secondary analysis to compare once daily dosing vs. twice daily dosing. . The statistical model was a logistic regression which included treatment and centre.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7856</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.599</ci_lower_limit>
            <ci_upper_limit>1.473</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 225 mg bid vs. Enoxaparin 40 mg qd comparison. Secondary analysis, active control used as reference. The statistical model was a logistic regression which included treatment and centre.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.469</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.302</ci_lower_limit>
            <ci_upper_limit>0.727</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 150 mg bid vs. Enoxaparin 40 mg qd comparison. Secondary analysis, active control used as reference. The statistical model was a logistic regression which included treatment and centre.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0401</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.647</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.427</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 50 mg bid vs. Enoxaparin 40 mg qd comparison. Secondary analysis, active control used as reference. The statistical model was a logistic regression which included treatment and centre.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2446</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.249</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.859</ci_lower_limit>
            <ci_upper_limit>1.817</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With VTE Events and All Cause Mortality</title>
        <description>Deep venous thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or Pulmonary Embolism (PE) confirmed by objective testing and all deaths.</description>
        <time_frame>Treatment period (up to day 8+/-2 days visit)</time_frame>
        <population>Full Analysis Set (FAS) population. This included all randomised patients who had at least one subcutaneous injection and one oral dose of study medication and with confirmed VTE data post surgery</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg Bid</title>
            <description>Dabigatran 50 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 150 mg Bid</title>
            <description>Dabigatran 150 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 225 mg Bid</title>
            <description>Dabigatran 225 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 300 mg qd</title>
            <description>Dabigatran 300 mg qd (once daily) oral</description>
          </group>
          <group group_id="O5">
            <title>Enoxaparin 40 mg qd</title>
            <description>Enoxaparin 40 mg qd (once daily) subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With VTE Events and All Cause Mortality</title>
          <description>Deep venous thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or Pulmonary Embolism (PE) confirmed by objective testing and all deaths.</description>
          <population>Full Analysis Set (FAS) population. This included all randomised patients who had at least one subcutaneous injection and one oral dose of study medication and with confirmed VTE data post surgery</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="375"/>
                <count group_id="O3" value="381"/>
                <count group_id="O4" value="371"/>
                <count group_id="O5" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 225 mg bid vs. BIBR 1048 50 mg bid comparison. The primary objective of the trial was to establish a dose relationship among BIBR 1048 doses studied in the prevention of VTE. The statistical model was a logistic regression which included treatment and centre..</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Dose relationship tested using a hierarchical testing procedure to preserve type I error rate at 5%. 225 mg bid was compared to 50 mg bid. If a difference significant at 5% level was found, then 150 mg bid was compared to 50 mg bid</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.375</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.244</ci_lower_limit>
            <ci_upper_limit>0.577</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 150 mg bid vs. BIBR 1048 50 mg bid comparison. The primary objective of the trial was to establish a dose relationship among BIBR 1048 doses studied in the prevention of VTE. The statistical model was a logistic regression which included treatment and centre..</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>Dose relationship tested using a hierarchical testing procedure to preserve type I error rate at 5%. 225 mg bid was compared to 50 mg bid. If a difference significant at 5% level was found, then 150 mg bid was compared to 50 mg bid</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.518</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.344</ci_lower_limit>
            <ci_upper_limit>0.778</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 300 mg qd vs. BIBR 1048 150 mg bid comparison. Secondary analysis to compare once daily dosing vs. twice daily dosing. . The statistical model was a logistic regression which included treatment and centre.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7856</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.599</ci_lower_limit>
            <ci_upper_limit>1.473</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 225 mg bid vs. Enoxaparin 40 mg qd comparison. Secondary analysis, active control used as reference. The statistical model was a logistic regression which included treatment and centre.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.469</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.302</ci_lower_limit>
            <ci_upper_limit>0.727</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 150 mg bid vs. Enoxaparin 40 mg qd comparison. Secondary analysis, active control used as reference. The statistical model was a logistic regression which included treatment and centre.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0401</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.647</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.427</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 50 mg bid vs. Enoxaparin 40 mg qd comparison. Secondary analysis, active control used as reference. The statistical model was a logistic regression which included treatment and centre.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2446</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.249</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.859</ci_lower_limit>
            <ci_upper_limit>1.817</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Proximal DVT, PE (Pulmonary Embolism) and VTE Related Mortality</title>
        <description>Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period or PE confirmed by objective testing plus VTE related mortality</description>
        <time_frame>Treatment period (up to day 10)</time_frame>
        <population>Full Analysis Set (FAS) population. This included all randomised patients who had at least one subcutaneous injection and one oral dose of study medication and with confirmed VTE data post surgery</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg Bid</title>
            <description>Dabigatran 50 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 150 mg Bid</title>
            <description>Dabigatran 150 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 225 mg Bid</title>
            <description>Dabigatran 225 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 300 mg qd</title>
            <description>Dabigatran 300 mg qd (once daily) oral</description>
          </group>
          <group group_id="O5">
            <title>Enoxaparin 40 mg qd</title>
            <description>Enoxaparin 40 mg qd (once daily) subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Proximal DVT, PE (Pulmonary Embolism) and VTE Related Mortality</title>
          <description>Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period or PE confirmed by objective testing plus VTE related mortality</description>
          <population>Full Analysis Set (FAS) population. This included all randomised patients who had at least one subcutaneous injection and one oral dose of study medication and with confirmed VTE data post surgery</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="375"/>
                <count group_id="O3" value="381"/>
                <count group_id="O4" value="371"/>
                <count group_id="O5" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 225 mg bid vs. BIBR 1048 50 mg bid, same methodology as primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0373</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.334</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.199</ci_lower_limit>
            <ci_upper_limit>0.938</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 150 mg bid vs. BIBR 1048 50 mg bid, same methodology as primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6659</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.837</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.374</ci_lower_limit>
            <ci_upper_limit>1.875</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 150 mg bid vs. BIBR 1048 300 mg qd, same methodology as primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1882</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.505</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.183</ci_lower_limit>
            <ci_upper_limit>1.397</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 50 mg bid vs. Enoxaparin 40 mg qd, same methodology as primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5566</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.805</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 150 mg bid vs. Enoxaparin 40 mg qd, same methodology as primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3253</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.674</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.307</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 225 mg bid vs. Enoxaparin 40 mg qd, same methodology as primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0114</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.269</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.097</ci_lower_limit>
            <ci_upper_limit>0.744</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Proximal DVT</title>
        <description>Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period</description>
        <time_frame>Treatment period (up to day 8+/-2 days visit)</time_frame>
        <population>Full Analysis Set (FAS) population. This included all randomised patients who had at least one subcutaneous injection and one oral dose of study medication and with confirmed VTE data post surgery</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg Bid</title>
            <description>Dabigatran 50 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 150 mg Bid</title>
            <description>Dabigatran 150 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 225 mg Bid</title>
            <description>Dabigatran 225 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 300 mg qd</title>
            <description>Dabigatran 300 mg qd (once daily) oral</description>
          </group>
          <group group_id="O5">
            <title>Enoxaparin 40 mg qd</title>
            <description>Enoxaparin 40 mgqd (once daily) subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Proximal DVT</title>
          <description>Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period</description>
          <population>Full Analysis Set (FAS) population. This included all randomised patients who had at least one subcutaneous injection and one oral dose of study medication and with confirmed VTE data post surgery</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="375"/>
                <count group_id="O3" value="381"/>
                <count group_id="O4" value="371"/>
                <count group_id="O5" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 225 mg bid vs. BIBR 1048 50 mg bid, same methodology as primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.332</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.118</ci_lower_limit>
            <ci_upper_limit>0.931</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 150 mg bid vs. BIBR 1048 50 mg bid, same methodology as primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3884</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.687</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.293</ci_lower_limit>
            <ci_upper_limit>1.611</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 150 mg bid vs. BIBR 1048 300 mg qd, same methodology as primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3674</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.616</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.215</ci_lower_limit>
            <ci_upper_limit>1.766</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 50 mg bid vs. Enoxaparin 40 mg qd, same methodology as primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5663</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.809</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.393</ci_lower_limit>
            <ci_upper_limit>1.668</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 150 mg bid vs. Enoxaparin 40 mg qd, same methodology as primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1678</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.556</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.242</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 225 mg bid vs. Enoxaparin 40 mg qd, same methodology as primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0113</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.269</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.097</ci_lower_limit>
            <ci_upper_limit>0.743</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Major Bleeding Events (MBE)</title>
        <time_frame>From approximately 14 days prior to surgery to 4-6 weeks post surgery</time_frame>
        <population>Safety Set (SAFE) population. This included all randomised patients who were treated and who had any available data</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg Bid</title>
            <description>Dabigatran 50 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 150 mg Bid</title>
            <description>Dabigatran 150 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 225 mg Bid</title>
            <description>Dabigatran 225 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 300 mg qd</title>
            <description>Dabigatran 300 mg qd (once daily) oral</description>
          </group>
          <group group_id="O5">
            <title>Enoxaparin 40 mg qd</title>
            <description>Enoxaparin 40mg qd (once daily) subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Bleeding Events (MBE)</title>
          <population>Safety Set (SAFE) population. This included all randomised patients who were treated and who had any available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="393"/>
                <count group_id="O4" value="385"/>
                <count group_id="O5" value="392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 225 mg bid vs. BIBR 1048 50 mg bid, same methodology as for primary endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0077</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>15.818</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.077</ci_lower_limit>
            <ci_upper_limit>120.474</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 150 mg bid vs. BIBR 1048 50 mg bid, same methodology as for primary endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0062</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>16.907</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.229</ci_lower_limit>
            <ci_upper_limit>128.238</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 150 mg bid vs. BIBR 1048 300 mg qd, same methodology as for primary endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7192</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.136</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.567</ci_lower_limit>
            <ci_upper_limit>2.276</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 50 mg bid vs. Enoxaparin 40 mg qd, same methodology as for primary endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0472</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.121</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.015</ci_lower_limit>
            <ci_upper_limit>0.974</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 150 mg bid vs. Enoxaparin 40 mg qd, same methodology as for primary endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1043</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.049</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.862</ci_lower_limit>
            <ci_upper_limit>4.868</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>BIBR 1048 225 mg bid vs. Enoxaparin 40 mg qd, same methodology as for primary endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1448</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.917</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.799</ci_lower_limit>
            <ci_upper_limit>4.597</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Blood Loss</title>
        <description>Volume of blood loss was to be analysed using an analysis of variance (ANOVA), which included treatment and centre.</description>
        <time_frame>Day 1 (Day of surgery)</time_frame>
        <population>Safety Set (SAFE) population. This included all randomised patients who were treated and who had any available data</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg Bid</title>
            <description>Dabigatran 50 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 150 mg Bid</title>
            <description>Dabigatran 150 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 225 mg Bid</title>
            <description>Dabigatran 225 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 300 mg qd</title>
            <description>Dabigatran 300 mg qd (once daily) oral</description>
          </group>
          <group group_id="O5">
            <title>Enoxaparin 40 mg qd</title>
            <description>Enoxaparin 40 mg qd (once daily) subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Blood Loss</title>
          <description>Volume of blood loss was to be analysed using an analysis of variance (ANOVA), which included treatment and centre.</description>
          <population>Safety Set (SAFE) population. This included all randomised patients who were treated and who had any available data</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="393"/>
                <count group_id="O4" value="385"/>
                <count group_id="O5" value="392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="523.3" spread="845.8"/>
                    <measurement group_id="O2" value="1538.4" spread="1474.5"/>
                    <measurement group_id="O3" value="631.4" spread="720.9"/>
                    <measurement group_id="O4" value="910.3" spread="918.3"/>
                    <measurement group_id="O5" value="945.5" spread="651.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Transfusions Due to Bleedings</title>
        <description>Percentage of patients requiring transfusions due to bleeding .Rate of need of transfusion were to be analysed using a logistic regression with treatment and centre.</description>
        <time_frame>Day 1 (Day of surgery)</time_frame>
        <population>Safety Set (SAFE) population. This included all randomised patients who were treated and who had any available data</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg Bid</title>
            <description>Dabigatran 50 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 150 mg Bid</title>
            <description>Dabigatran 150 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 225 mg Bid</title>
            <description>Dabigatran 225 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 300 mg qd</title>
            <description>Dabigatran 300 mg qd (once daily) oral</description>
          </group>
          <group group_id="O5">
            <title>Enoxaparin 40 mg qd</title>
            <description>Enoxaparin 40 mg qd (once daily) subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Transfusions Due to Bleedings</title>
          <description>Percentage of patients requiring transfusions due to bleeding .Rate of need of transfusion were to be analysed using a logistic regression with treatment and centre.</description>
          <population>Safety Set (SAFE) population. This included all randomised patients who were treated and who had any available data</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="393"/>
                <count group_id="O4" value="385"/>
                <count group_id="O5" value="392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26"/>
                    <measurement group_id="O2" value="5.38"/>
                    <measurement group_id="O3" value="4.07"/>
                    <measurement group_id="O4" value="4.94"/>
                    <measurement group_id="O5" value="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0063</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>16.871</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.221</ci_lower_limit>
            <ci_upper_limit>128.142</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>22.338</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.983</ci_lower_limit>
            <ci_upper_limit>167.268</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7973</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.919</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.483</ci_lower_limit>
            <ci_upper_limit>1.750</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0097</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.068</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.522</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2375</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.522</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.758</ci_lower_limit>
            <ci_upper_limit>3.058</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7104</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.150</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.550</ci_lower_limit>
            <ci_upper_limit>2.403</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant, Minor or Any Bleeding Events</title>
        <description>Number of participants with Clinically Significant, minor or any bleeding events. Clinically significant bleeding events are defined as
Spontaneous skin haematoma larger than &gt;25 cm²
Wound haematoma &gt;100 cm²
Spontaneous nose bleed &gt;5 minutes
Macroscopic haematurea, either spontaneous or lasting more than 24 hours if associated with an intervention
Spontaneous rectal bleeding (more than spot on toilet paper)
Gingival bleeding &gt;5 minutes
Any other bleeding event considered as clinically significant by the investigator All other bleeding events that did not fulfil the criteria of MBE or clinically significant bleeding event were classified as minor bleeding events.</description>
        <time_frame>Treatment period (up to day 8+/-2 days visit)</time_frame>
        <population>Safety Set (SAFE) population. This included all randomised patients who were treated and who had any available data</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg Bid</title>
            <description>Dabigatran 50 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 150 mg Bid</title>
            <description>Dabigatran 50 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 225 mg Bid</title>
            <description>Dabigatran 225 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 300 mg qd</title>
            <description>Dabigatran 300 mg qd (once daily) oral</description>
          </group>
          <group group_id="O5">
            <title>Enoxaparin 40 mg qd</title>
            <description>Enoxaparin 40 mg qd (once daily) subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant, Minor or Any Bleeding Events</title>
          <description>Number of participants with Clinically Significant, minor or any bleeding events. Clinically significant bleeding events are defined as
Spontaneous skin haematoma larger than &gt;25 cm²
Wound haematoma &gt;100 cm²
Spontaneous nose bleed &gt;5 minutes
Macroscopic haematurea, either spontaneous or lasting more than 24 hours if associated with an intervention
Spontaneous rectal bleeding (more than spot on toilet paper)
Gingival bleeding &gt;5 minutes
Any other bleeding event considered as clinically significant by the investigator All other bleeding events that did not fulfil the criteria of MBE or clinically significant bleeding event were classified as minor bleeding events.</description>
          <population>Safety Set (SAFE) population. This included all randomised patients who were treated and who had any available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="393"/>
                <count group_id="O4" value="385"/>
                <count group_id="O5" value="392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinically significant bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Analyses</title>
        <description>Number of patients with possible clinically significant abnormalities, i.e. with values out of normal range.
Normal ranges are defined as:
Haematocrit [%]: (0.35-0.45) for women and (0.39−0.51) for men Haemoglobin [g/dL]: (11.6−15.4) for women and (13.2−17.3) for men White Blood Cell count [10^9/L]: (4-10.3) for women and (3.9−10.3) for men Platelets [10^9/L]: (145-420) for women and men Sodium [mmol/L]: (135-146) for women and men Potassium [mmol/L]: (3.5-5) for women and men Aspartate aminotransferase (AST) [U/L]: (11-37) for women and (11-39) for men Alanine aminotransferase (ALT) [U/L]: (8-43) for women and (8-45) for men Alkaline Phosphatase [U/L]: (36-118) for women and (35-123) for men Creatinine [mg/dL]: (0.57-1.06)for women and (0.72−1.3) for men Bilirubin, total [mg/dL]: (0.22-1.28) for women and men Uric acid [mg/dL]: (2.4-6.47) for women and men</description>
        <time_frame>Screening to end of treatment</time_frame>
        <population>Safety Set (SAFE) population. This included all randomised patients who were treated and who had any available data</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg Bid</title>
            <description>Dabigatran 50 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 150 mg Bid</title>
            <description>Dabigatran 150 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 225 mg Bid</title>
            <description>Dabigatran 225 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 300 mg qd</title>
            <description>Dabigatran 300 mg qd (once daily) oral</description>
          </group>
          <group group_id="O5">
            <title>Enoxaparin 40 mg qd</title>
            <description>Enoxaparin 40 mg qd (once daily) subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Analyses</title>
          <description>Number of patients with possible clinically significant abnormalities, i.e. with values out of normal range.
Normal ranges are defined as:
Haematocrit [%]: (0.35-0.45) for women and (0.39−0.51) for men Haemoglobin [g/dL]: (11.6−15.4) for women and (13.2−17.3) for men White Blood Cell count [10^9/L]: (4-10.3) for women and (3.9−10.3) for men Platelets [10^9/L]: (145-420) for women and men Sodium [mmol/L]: (135-146) for women and men Potassium [mmol/L]: (3.5-5) for women and men Aspartate aminotransferase (AST) [U/L]: (11-37) for women and (11-39) for men Alanine aminotransferase (ALT) [U/L]: (8-43) for women and (8-45) for men Alkaline Phosphatase [U/L]: (36-118) for women and (35-123) for men Creatinine [mg/dL]: (0.57-1.06)for women and (0.72−1.3) for men Bilirubin, total [mg/dL]: (0.22-1.28) for women and men Uric acid [mg/dL]: (2.4-6.47) for women and men</description>
          <population>Safety Set (SAFE) population. This included all randomised patients who were treated and who had any available data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="393"/>
                <count group_id="O4" value="385"/>
                <count group_id="O5" value="392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Haematocrit decrease (N=325,324,339,320,340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoglobin decrease (N=325,324,339,320,340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="129"/>
                    <measurement group_id="O3" value="148"/>
                    <measurement group_id="O4" value="129"/>
                    <measurement group_id="O5" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell ct. decr.(N=325,324,339,320,340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets decrease (N=325,324,339,320,340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets increase (N=325,324,339,320,340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium decrease (N=340,334,344,327,352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium decrease (N=340,334,344,326,352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium increase (N=340,334,344,326,352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST increase (N=340,334,344,327,352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT increase (N=340,334,344,327,352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase incr. (N=340,334,344,327,352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine increase (N=340,334,344,327,352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, total increase (N=340,334,344,327,352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid increase (N=340,334,344,327,352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration (Cmax) of Dabigatran</title>
        <description>Maximum plasma concentration of Dabigatran (at steady-state) and Pre-dose plasma concentrations at steady state.
Cmax represents the maximum concentration of Dabigatran in plasma. Cmax,ss represents the maximum concentration of Dabigatran in plasma at steady state.
Cpre,ss represents pre-dose concentration of Dabigatran in plasma at steady state</description>
        <time_frame>Day 1 to end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg Bid</title>
            <description>Dabigatran 50 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 150 mg Bid</title>
            <description>Dabigatran 150 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 225 mg Bid</title>
            <description>Dabigatran 225 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 300 mg qd</title>
            <description>Dabigatran 300 mg qd (once daily) oral</description>
          </group>
          <group group_id="O5">
            <title>Enoxaparin 40 mg qd</title>
            <description>Enoxaparin 40 mg qd (once daily) subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration (Cmax) of Dabigatran</title>
          <description>Maximum plasma concentration of Dabigatran (at steady-state) and Pre-dose plasma concentrations at steady state.
Cmax represents the maximum concentration of Dabigatran in plasma. Cmax,ss represents the maximum concentration of Dabigatran in plasma at steady state.
Cpre,ss represents pre-dose concentration of Dabigatran in plasma at steady state</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="365"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="365"/>
                <count group_id="O4" value="351"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax (N=88, 83, 84, 96, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="115"/>
                    <measurement group_id="O2" value="60.5" spread="97.3"/>
                    <measurement group_id="O3" value="79.9" spread="94.7"/>
                    <measurement group_id="O4" value="132" spread="81.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax at steady-state (N=87, 74, 79, 85, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" spread="64.6"/>
                    <measurement group_id="O2" value="165" spread="63.6"/>
                    <measurement group_id="O3" value="257" spread="62.7"/>
                    <measurement group_id="O4" value="271" spread="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cpre at steady-state</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" spread="70.7"/>
                    <measurement group_id="O2" value="70.3" spread="87.3"/>
                    <measurement group_id="O3" value="113" spread="80.9"/>
                    <measurement group_id="O4" value="38.0" spread="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve During a Dosing Interval</title>
        <description>Area under the plasma concentration-time curve during a dosing interval (at steady-state). The AUC0-12h (for b.i.d. treatment regimens) and AUC0-24h (300 mg q.d.) after the first dose on day of surgery calculated by extrapolation using the elimination rate constant, reported only if the extrapolated fraction of AUC was less than 30 % of the total AUC.</description>
        <time_frame>up to day 8+/-2 days visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg Bid</title>
            <description>Dabigatran 50 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 150 mg Bid</title>
            <description>Dabigatran 150 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 225 mg Bid</title>
            <description>Dabigatran 225 mg bid (twice daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 300 mg qd</title>
            <description>Dabigatran 300 mg qd (once daily) oral</description>
          </group>
          <group group_id="O5">
            <title>Enoxaparin 40 mg qd</title>
            <description>Enoxaparin 40 mg qd (once daily) subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve During a Dosing Interval</title>
          <description>Area under the plasma concentration-time curve during a dosing interval (at steady-state). The AUC0-12h (for b.i.d. treatment regimens) and AUC0-24h (300 mg q.d.) after the first dose on day of surgery calculated by extrapolation using the elimination rate constant, reported only if the extrapolated fraction of AUC was less than 30 % of the total AUC.</description>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="76"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC during a dosing interval (N=13,12,21,72,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229" spread="88.1"/>
                    <measurement group_id="O2" value="636" spread="56.2"/>
                    <measurement group_id="O3" value="605" spread="91.6"/>
                    <measurement group_id="O4" value="1610" spread="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC during a dosing interval at steady-state</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350" spread="66.8"/>
                    <measurement group_id="O2" value="1250" spread="64.8"/>
                    <measurement group_id="O3" value="1910" spread="64.9"/>
                    <measurement group_id="O4" value="2450" spread="76.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days +/- 2 days</time_frame>
      <desc>Time frame is from first dose of randomised treatment up to the end of treatment including 6 days after last intake.</desc>
      <group_list>
        <group group_id="E1">
          <title>BIBR 1048 50 mg Bid</title>
          <description>Dabigatran 50 mg bid (twice daily) oral</description>
        </group>
        <group group_id="E2">
          <title>BIBR 1048 150 mg Bid</title>
          <description>Dabigatran 150 mg bid (twice daily) oral</description>
        </group>
        <group group_id="E3">
          <title>BIBR 1048 225 mg Bid</title>
          <description>Dabigatran 225 mg bid (twice daily) oral</description>
        </group>
        <group group_id="E4">
          <title>BIBR 1048 300 mg qd</title>
          <description>Dabigatran 300 mg qd (once daily) oral</description>
        </group>
        <group group_id="E5">
          <title>Enoxaparin 40 mg qd</title>
          <description>Enoxaparin 40 mg qd (once daily) subcutaneous injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA(4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemolytic anaemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypocoagulable state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Leukopenia NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bradycardia NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiac disorder NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Abdominal pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Diverticulitis intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Inflammation localised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Oedema lower limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis infective NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cystitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastroenteritis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Implant infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Meningitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Post-operative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Wound infection NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Femur fracture NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Intraoperative haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Joint dislocation NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Joint dislocation postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Joint ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Post procedural drainage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Post procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Postoperative haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase NOS increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bone disorder NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pain in limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Colon neoplasm NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lung neoplasm NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Peripheral neuropathy NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Radiculitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Renal failure aggravated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diaphragmatic paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Dyspnoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial haemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Deep venous thrombosis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Haematoma NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Haemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypotension NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Venous thrombosis deep limb</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA(4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="242" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="267" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="256" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="267" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="258" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="105" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="111" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="76" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural drainage</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache NOS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma NOS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypotension NOS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Venous thrombosis deep limb</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="390"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="393"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="385"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

